190 related articles for article (PubMed ID: 8492403)
1. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.
Kessler DA
JAMA; 1993 Jun; 269(21):2765-8. PubMed ID: 8492403
[No Abstract] [Full Text] [Related]
2. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.
Kessler DA
J Am Podiatr Med Assoc; 1994 Jan; 84(1):35-8. PubMed ID: 8295131
[No Abstract] [Full Text] [Related]
3. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.
Kessler DA
Gen Hosp Psychiatry; 1994 Mar; 16(2):96-101; discussion 102. PubMed ID: 8039699
[No Abstract] [Full Text] [Related]
4. MedWatch. On lookout for medical product problems.
Ropp KL
FDA Consum; 1993 Nov; 27(9):14-7. PubMed ID: 10130376
[No Abstract] [Full Text] [Related]
5. MEDWatch: the new FDA medical products reporting program.
Kessler DA
Am J Hosp Pharm; 1993 Jun; 50(6):1151-2. PubMed ID: 8517452
[No Abstract] [Full Text] [Related]
6. MedWatch program.
White GG
Int J Trauma Nurs; 1998; 4(3):100-3. PubMed ID: 9855977
[No Abstract] [Full Text] [Related]
7. Watching out for public safety.
Laskin DM
J Oral Maxillofac Surg; 1993 Sep; 51(9):959. PubMed ID: 8355100
[No Abstract] [Full Text] [Related]
8. Postmarketing follow-up: physicians have key role.
Goldsmith MF
JAMA; 1985 Oct; 254(16):2217. PubMed ID: 4046146
[No Abstract] [Full Text] [Related]
9. Monitoring adverse drug events: the Food and Drug Administration MedWatch reporting system.
Landow L
Reg Anesth Pain Med; 1998; 23(6 Suppl 2):190-3. PubMed ID: 9845393
[No Abstract] [Full Text] [Related]
10. Evaluating the completeness and accuracy of MedWatch data.
Getz KA; Stergiopoulos S; Kaitin KI
Am J Ther; 2014; 21(6):442-6. PubMed ID: 23011177
[TBL] [Abstract][Full Text] [Related]
11. Risk Evaluation and Mitigation Strategy (REMS): FDA Perspective on What Physicians Need to Know.
Slatko GH
Am Fam Physician; 2015 Nov; 92(9):771-2. PubMed ID: 26554468
[No Abstract] [Full Text] [Related]
12. Postmarketing surveillance: beyond MEDWatch.
Faich GA
JAMA; 1993 Nov; 270(18):2180. PubMed ID: 8411596
[No Abstract] [Full Text] [Related]
13. MedWatch targets reporting of serious adverse events.
VanAmringe M
Jt Comm Perspect; 1993; 13(4):15. PubMed ID: 10129237
[No Abstract] [Full Text] [Related]
14. MedWatch: the new medical products reporting program.
Couig MP; Merkatz RB
Am J Nurs; 1993 Aug; 93(8):65-8. PubMed ID: 8256839
[No Abstract] [Full Text] [Related]
15. MedWatch: the FDA medical products reporting program.
Rheinstein PH
Am Fam Physician; 1993 Sep; 48(4):636-8. PubMed ID: 8379493
[No Abstract] [Full Text] [Related]
16. The prescription drug user fee act: active postmarketing drug surveillance and safety.
Lyles A
Clin Ther; 2002 May; 24(5):800-2. PubMed ID: 12075947
[No Abstract] [Full Text] [Related]
17. Vaccine adverse event reporting: the importance of follow-up.
Varricchio F
Expert Rev Vaccines; 2005 Aug; 4(4):445-8. PubMed ID: 16117700
[No Abstract] [Full Text] [Related]
18. A one-year perspective on MedWatch: the Food and Drug Administration's new medical products reporting program.
Gruchalla RS
J Allergy Clin Immunol; 1995 Jun; 95(6):1153-7. PubMed ID: 7797782
[No Abstract] [Full Text] [Related]
19. Food and Drug Administration update. The MedWatch program.
White GG; Love L
J Toxicol Clin Toxicol; 1998; 36(1-2):145-9. PubMed ID: 9541064
[No Abstract] [Full Text] [Related]
20. MedWatch. FDA's 'heads up' on medical product safety.
Henkel J
FDA Consum; 1998; 32(6):10-2, 15. PubMed ID: 9854445
[No Abstract] [Full Text] [Related]
[Next] [New Search]
